Patents Examined by Carla J. Myers
  • Patent number: 10844436
    Abstract: The present invention is directed to methods of prognosing, treating, or managing treatment of cancer in a subject. These methods involve selecting a subject having cancer, obtaining, from the selected subject, a sample containing exosomes, recovering the exosomes from the sample, and isolating the double-stranded DNA from within the exosomes. The isolated double-stranded DNA is then used to detect the presence or absence of one or more genetic mutations associated with cancer, quantify the amount of isolated double-stranded DNA from the recovered exosomes in the sample, detect the methylation status of the isolated double-stranded DNA, or quantify the amount isolated double-stranded DNA able to enter a recipient cell. The prognosing, treating, or managing treatment is carried out based on this information.
    Type: Grant
    Filed: April 1, 2015
    Date of Patent: November 24, 2020
    Assignees: CORNELL UNIVERSITY, SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH
    Inventors: David C. Lyden, Hector Peinado Selgas, Haiying Zhang, Basant Kumar Thakur, Annette Becker, Jacqueline Bromberg
  • Patent number: 10844434
    Abstract: Compositions and methods for the detection and treatment of ADHD are provided.
    Type: Grant
    Filed: March 7, 2016
    Date of Patent: November 24, 2020
    Assignee: The Children's Hospital of Philadelphia
    Inventors: Joseph Glessner, Josephine Elia, Hakon Hakonarson
  • Patent number: 10815528
    Abstract: The present invention relates to a method for diagnosis of Inflammatory Bowel Disease (IBD) based on the determination of expression profiles of miRNAs representative for diagnosis of IBD compared to a reference. In addition, the present invention relates to a kit for diagnosis of IBD comprising means for determining expression profiles of miRNAs representative for IBD.
    Type: Grant
    Filed: July 23, 2015
    Date of Patent: October 27, 2020
    Assignee: Hummingbird Diagnostics GmbH
    Inventors: Thomas Brefort, Andre Franke, Georg Hemmrich-Stanisak, Matthias Hubenthal, Matthias Scheffler
  • Patent number: 10815522
    Abstract: Pancreatic adenocarcinoma has the worst overall mortality of any solid tumor, with only 7% of patients surviving after 5 years. To evaluate the clinical implications of genomic alterations in this low cellularity tumor type, we deeply sequenced the genomes of 101 enriched pancreatic adenocarcinomas from patients who underwent potentially curative resections and used non-invasive approaches to examine tumor specific mutations in the circulation of these patients. These analyses revealed somatic mutations in chromatin regulating genes including MLL and ARID1A in 20% of patients that were associated with improved survival. Liquid biopsy analyses of cell free plasma DNA revealed that 43% of patients with localized disease had detectable circulating tumor DNA (ctDNA) in their blood at the time of diagnosis. Detection of ctDNA after resection predicted clinical relapse and poor outcome, and disease recurrence by ctDNA was detected 6.5 months earlier than with standard CT imaging.
    Type: Grant
    Filed: February 18, 2016
    Date of Patent: October 27, 2020
    Assignee: The Johns Hopkins University
    Inventors: Victor Velculescu, Mark Sausen, Vilmos Adleff, Jillian Phallen
  • Patent number: 10808239
    Abstract: Methods of isolating DNA of a fetus of an ongoing pregnancy are provided according to the present invention which include obtaining a maternal endocervical sample containing maternal cells and fetal extravillous trophoblast cells from a pregnant subject; isolating fetal extravillous trophoblast cells from the maternal endocervical sample, producing isolated fetal extravillous trophoblast cells contaminated with maternal DNA; lysing the isolated fetal extravillous trophoblast cells; isolating fetal nuclei from the lysed fetal extravillous trophoblast cells, producing isolated fetal nuclei, thereby removing at least a portion of the contaminating maternal DNA; and purifying genomic DNA from the isolated fetal nuclei, producing purified fetal genomic DNA. The purified fetal genomic DNA can be assayed to determine a characteristic of a genomic DNA sequence of the purified fetal genomic DNA, thereby determining a characteristic of DNA of a fetus of an ongoing pregnancy.
    Type: Grant
    Filed: April 6, 2017
    Date of Patent: October 20, 2020
    Assignee: Wayne State University
    Inventors: Sascha Drewlo, D. Randall Armant
  • Patent number: 10787707
    Abstract: Methods and reagents for determining a subject's predisposition for refractive error based on the presence of opsin gene exon 3 splicing defects are provided. In one aspect, the invention provides methods for determining a subject's predisposition for refractive error comprising: (a) testing a biological sample obtained from the subject to determine exon 3 splicing defects in one or more opsin gene; and (b) correlating the exon 3 splicing defects in the one or more opsin gene with a predisposition for refractive error.
    Type: Grant
    Filed: February 29, 2016
    Date of Patent: September 29, 2020
    Assignee: University of Washington
    Inventors: Jay Neitz, Maureen Neitz
  • Patent number: 10781490
    Abstract: Techniques are provided for detecting hematological disorders using cell-free DNA in a blood sample, e.g., using plasma or serum. For example, an assay can target one or more differentially-methylated regions specific to a particular hematological cell lineage (e.g., erythroblasts). A methylation level can be quantified from the assay to determine an amount of methylated or unmethylated DNA fragments in a cell-free mixture of the blood sample. The methylation level can be compared to one or more cutoff values, e.g., that correspond to a normal range for the particular hematological cell lineage as part of determining a level of a hematological disorder.
    Type: Grant
    Filed: May 30, 2017
    Date of Patent: September 22, 2020
    Assignee: The Chinese University of Hong Kong
    Inventors: Yuk-Ming Dennis Lo, Rossa Wai Kwun Chiu, Kwan Chee Chan, Kun Sun
  • Patent number: 10781492
    Abstract: The present invention relates to a method, in particular an in vitro method, for identifying CD8 positive subpopulations of a mammal, wherein said method comprises analyzing the bisulfite convertibility of at least one CpG position in the CD8 beta and CD8 alpha cell specific bisulfite convertibility gene region according to SEQ ID No. 1 and 2, wherein a bisulfite convertibility of at least one CpG position in said gene regions is indicative for a CD3+CD8+ and/or CD3+/?CD8+ cell. The analyses according to the invention can identify CD3+CD8+ and/or CD3+/?CD8+ cells on an epigenetic level and distinguish them from all other cells in complex samples, such as, for example, other blood cells.
    Type: Grant
    Filed: March 12, 2019
    Date of Patent: September 22, 2020
    Assignee: EPIONTIS GMBH
    Inventor: Sven Olek
  • Patent number: 10760131
    Abstract: Disclosed are methods of, and assay and kits for, detecting and diagnosing arterial plaque rupture using the expression of miR-222, mi-221 and circ284. Also disclosed are methods of treating arterial plaque rupture and methods of identifying agents for use thin the treatment of arterial plaque rupture.
    Type: Grant
    Filed: February 23, 2016
    Date of Patent: September 1, 2020
    Inventors: Thomas Cooper Woods, Hernan Antonio Bazan
  • Patent number: 10752962
    Abstract: Methods and compositions for detection of Neisseria gonorrhoeae are disclosed herein. In some embodiments, the presence or absence of N. gonorrhoeae in a sample is determined using nucleic acid-based testing methods using primers and/or probes that bind to opcA gene region of N. gonorrhoeae.
    Type: Grant
    Filed: June 6, 2018
    Date of Patent: August 25, 2020
    Assignee: Becton, Dickinson and Company
    Inventors: Keith Edward Thornton, Paul Madepogu, Danielle Koffenberger
  • Patent number: 10745764
    Abstract: Embodiments of the invention provide a method of genotyping a C. gattii sample, which can include forming a plurality of mixtures for nucleic amplification. The method can include amplification of specific sequences within the C. gattii genome that can provide definitive genotype information to distinguish between one or more types or subtypes of C. gattii.
    Type: Grant
    Filed: June 11, 2018
    Date of Patent: August 18, 2020
    Assignees: The Translational Genomics Research Institiute, Arizona Board of Regents on Behalf of Northern Arizona University
    Inventors: David Engelthaler, Elizabeth Driebe, Erin Kelley, Paul Keim
  • Patent number: 10738360
    Abstract: Disclosed is a method for assisting the detection of Alzheimer's disease or mild cognitive impairment, the method for assisting the highly accurate detection of Alzheimer's disease or mild cognitive impairment. In the method for assisting the detection of Alzheimer's disease or mild cognitive impairment, the amount of at least one miRNA selected from miR-122, miR-144, let-7f, miR-128-3p and miR-107 contained in a test sample separated from a living body is used as an indicator. A larger amount of miR-122 than that in a healthy individual, or a smaller amount of at least one miRNA selected from miR-144, let-7f, miR-128-3p and miR-107 than that in a healthy individual is indicative that the living body is more likely to have developed Alzheimer's disease or mild cognitive impairment.
    Type: Grant
    Filed: March 11, 2016
    Date of Patent: August 11, 2020
    Assignee: HIROSHIMA UNIVERSITY
    Inventors: Hidetoshi Tahara, Masayasu Matsumoto, Yu Ninose
  • Patent number: 10724096
    Abstract: This document provides methods and materials related to treating subjects having specific genetic variations associated with neurological disorders such as Parkinson's disease.
    Type: Grant
    Filed: September 4, 2015
    Date of Patent: July 28, 2020
    Assignee: POPULATION BIO, INC.
    Inventors: Eli Hatchwell, Peggy Eis
  • Patent number: 10724104
    Abstract: The disclosure concerns a prognostic method for determining at least one, or a combination, of the following: time to first treatment, response to treatment or overall survival for a patient presenting with a disease including or characterised by telomere shortening, including an assessment of the longest mean telomere length at which telomere end-end fusion events can be detected and then a determination of the mean telomere length in the fusogenic range (i.e. the range below that mean telomere length at which telomere end-end fusion events can be detected) and the subsequent use of the mean telomere length in the fusogenic range as a prognostic indicator.
    Type: Grant
    Filed: March 26, 2019
    Date of Patent: July 28, 2020
    Assignee: UNIVERSITY COLLEGE CARDIFF CONSULTANTS LIMITED
    Inventors: Duncan Baird, Chris Pepper, Christopher Fegan
  • Patent number: 10718774
    Abstract: Heritable mutations in the BRCA1 and BRCA2 and other genes in the DNA double-strand break (DSB) repair pathway increase risk of breast, ovarian and other cancers. In response to DNA breaks, the proteins encoded by these genes bind to each other and are transported into the nucleus to form nuclear foci and initiate homologous recombination. Flow cytometry-based functional variant analyses (FVAs) were developed to determine whether variants in BRCA1 or other DSB repair genes disrupted the binding of BRCA1 to its protein partners, the phosphorylation of p53 or the transport of the BRCA1complex to the nucleus in response to DNA damage. Each of these assays distinguished high-risk BRCA1 mutations from low-risk BRCA1 controls. Mutations in other DSB repair pathway genes produced molecular phenocopies with these assays. FVA assays may represent an adjunct to sequencing for categorizing VUS or may represent a stand-alone measure for assessing breast cancer risk.
    Type: Grant
    Filed: August 19, 2015
    Date of Patent: July 21, 2020
    Assignee: ALBERT EINSTEIN COLLEGE OF MEDICINE, INC.
    Inventors: Harry Ostrer, Johnny C. Loke, Alexander Pearlman
  • Patent number: 10718026
    Abstract: The present invention discloses a method of generating subsets of methylation specific markers from a set, having diagnostic power for various diseases, e.g. cancer of thyroid, breast, colon, or leukemia, in diverse samples; identified subsets of that set, as well as methods for the prognosis and diagnosis of diseases.
    Type: Grant
    Filed: January 28, 2010
    Date of Patent: July 21, 2020
    Assignee: AIT Austrian Institute of Technology GMBH
    Inventors: Andreas Weinhausel, Rudolf Pichler, Christa Nohammer
  • Patent number: 10711302
    Abstract: The Invention relates to a method of predicting resistance to infectious pancreatic necrosis in salmon, the method comprising determining the alleles present at a DNA polymorphism in the salmon and predicting whether or not the salmon is resistant to infectious pancreatic necrosis based on the determination of the alleles. The invention also relates to a method of selecting a salmon for use as broodstock, wherein the salmon is selected based on the prediction by the first method that the salmon will have resistance to infectious pancreatic necrosis.
    Type: Grant
    Filed: December 20, 2017
    Date of Patent: July 14, 2020
    Assignee: AquaGen AS
    Inventor: Thomas Moen
  • Patent number: 10711301
    Abstract: The Invention relates to a method of predicting resistance to infectious pancreatic necrosis in salmon, the method comprising determining the alleles present at a DNA polymorphism in the salmon and predicting whether or not the salmon is resistant to infectious pancreatic necrosis based on the determination of the alleles. The invention also relates to a method of selecting a salmon for use as broodstock, wherein the salmon is selected based on the prediction by the first method that the salmon will have resistance to infectious pancreatic necrosis.
    Type: Grant
    Filed: December 20, 2017
    Date of Patent: July 14, 2020
    Assignee: AquaGen AS
    Inventor: Thomas Moen
  • Patent number: 10704098
    Abstract: Compositions and methods for the treatment and diagnosis of eosinophilic esophagitis disclosed.
    Type: Grant
    Filed: October 29, 2015
    Date of Patent: July 7, 2020
    Assignee: The Children's Hospital of Philadelphia
    Inventors: Hakon Hakonarson, Patrick Sleiman
  • Patent number: 10689710
    Abstract: The present technology relates to methods for determining whether a patient diagnosed with breast cancer, colorectal cancer, melanoma or lung cancer will benefit from or is predicted to be responsive to treatment with an individual therapeutic agent or a specific combination of therapeutic agents. These methods are based on screening a patient's solid tumors and detecting alterations in target nucleic acid sequences corresponding to a specific set of cancer-related genes. Kits for use in practicing the methods are also provided.
    Type: Grant
    Filed: October 28, 2015
    Date of Patent: June 23, 2020
    Assignee: Quest Diagnostics Investments Incorporated
    Inventors: Heather Sanders, Kevin Qu, James Prentice, Frederic Waldman